[go: up one dir, main page]

MX2015001370A - N-alquil 2-(disustituido)alquiladenosin-5-uronamidas como agonistas a2a. - Google Patents

N-alquil 2-(disustituido)alquiladenosin-5-uronamidas como agonistas a2a.

Info

Publication number
MX2015001370A
MX2015001370A MX2015001370A MX2015001370A MX2015001370A MX 2015001370 A MX2015001370 A MX 2015001370A MX 2015001370 A MX2015001370 A MX 2015001370A MX 2015001370 A MX2015001370 A MX 2015001370A MX 2015001370 A MX2015001370 A MX 2015001370A
Authority
MX
Mexico
Prior art keywords
uronamides
alkynyladenosine
disubstituted
alkyl
agonists
Prior art date
Application number
MX2015001370A
Other languages
English (en)
Other versions
MX367879B (es
Inventor
Robert Thompson
Anthony Beauglehole
Guoquan Wang
Original Assignee
Lewis And Clark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lewis And Clark Pharmaceuticals Inc filed Critical Lewis And Clark Pharmaceuticals Inc
Publication of MX2015001370A publication Critical patent/MX2015001370A/es
Publication of MX367879B publication Critical patent/MX367879B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)

Abstract

La presente invención proporciona n-alquil 2-alquiniladenosina (disustituida)-5-uronamidas y sus derivados y composiciones farmacéuticas que las contienen que son agonistas selectivos de los receptores de adenosina A2a (ARs). Estos compuestos y las composiciones son útiles como agentes farmacéticos.
MX2015001370A 2012-08-01 2013-07-31 N-alquil 2-(disustituido)alquiladenosin-5-uronamidas como agonistas a2a. MX367879B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261678605P 2012-08-01 2012-08-01
US201361787188P 2013-03-15 2013-03-15
PCT/US2013/053053 WO2014022577A1 (en) 2012-08-01 2013-07-31 N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as a2a agonists

Publications (2)

Publication Number Publication Date
MX2015001370A true MX2015001370A (es) 2016-04-26
MX367879B MX367879B (es) 2019-09-10

Family

ID=50025663

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001370A MX367879B (es) 2012-08-01 2013-07-31 N-alquil 2-(disustituido)alquiladenosin-5-uronamidas como agonistas a2a.

Country Status (15)

Country Link
US (1) US9067963B2 (es)
EP (1) EP2879683B1 (es)
JP (1) JP6545618B2 (es)
KR (1) KR20150036767A (es)
CN (1) CN104582709A (es)
AU (1) AU2013296420B2 (es)
BR (1) BR112015002249A2 (es)
CA (1) CA2880040A1 (es)
EA (1) EA027174B1 (es)
IL (1) IL236986A (es)
IN (1) IN2015DN00538A (es)
MX (1) MX367879B (es)
NZ (1) NZ703992A (es)
WO (1) WO2014022577A1 (es)
ZA (1) ZA201501350B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325171B1 (en) 2005-05-26 2013-10-09 Aldexa Therapeutics, Inc. Quinoline derivatives for treating retinal diseases
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US9822141B2 (en) * 2012-08-01 2017-11-21 Lewis And Clark Pharmaceuticals, Inc. N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. COMBINATION TREATMENT OF FLAMMABLE CONDITIONS AND DISEASES OF THE EYE
AU2018234919A1 (en) 2017-03-16 2019-09-19 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN114025763B (zh) * 2019-06-21 2023-09-12 中国人民解放军军事科学院军事医学研究院 腺苷类化合物、其可药用盐或其立体异构体及用途
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用
WO2024258897A1 (en) 2023-06-13 2024-12-19 Dem Biopharma, Inc. Alkoxypyridinyl and related compounds and their use in therapy
WO2025194014A1 (en) 2024-03-15 2025-09-18 Dem Biopharma, Inc. Hetero aryl modulators of apmap and uses thereof
WO2025194015A1 (en) 2024-03-15 2025-09-18 Dem Biopharma, Inc. Heteroaryl modulators of gpr84 and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH02104783A (ja) * 1988-10-11 1990-04-17 Kanai Hiroyuki スチールコードおよびタイヤ
DE68916036T2 (de) 1988-11-15 1994-09-29 Toa Eiyo Ltd Mittel zur behandlung und prophylaxe koronarer und zerebraler ischämischer erkrankungen.
US5283327A (en) 1989-06-20 1994-02-01 Yamasa Shoyu Kabushiki Kaisha Tri-O-acetyl-2-alkynyladenosines
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
JP3025557B2 (ja) * 1991-06-28 2000-03-27 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
CN1205188C (zh) 2000-03-23 2005-06-08 索尔瓦药物有限公司 具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
EP1537135B1 (en) 2002-09-09 2009-11-25 Cv Therapeutics, Inc. Adenosine a3 receptor agonists
EP1778712B1 (en) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006091896A2 (en) * 2005-02-25 2006-08-31 Adenosine Therapeutics, Llc Pyridyl substituted xanthines
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
DE602007012904D1 (de) * 2006-06-27 2011-04-14 Cbt Dev Lim Neue 2',3'-methylidenacetyladenosine prodrugs zur
US20080312160A1 (en) * 2007-04-09 2008-12-18 Guerrant Richard L Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
KR101464794B1 (ko) 2007-05-17 2014-11-27 길리애드 사이언시즈, 인코포레이티드 Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
US8293720B2 (en) 2007-12-20 2012-10-23 Dogwood Pharmaceuticals, Inc. Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
KR20120107065A (ko) * 2009-06-30 2012-09-28 포레스트 래보러토리즈 홀딩스 리미티드 Ａ２ａｒ 효현제용 알콕시 카르보닐 아미노 알키닐 아데노신 화합물 및 그 유도체

Also Published As

Publication number Publication date
CN104582709A (zh) 2015-04-29
US20140037538A1 (en) 2014-02-06
JP2015524440A (ja) 2015-08-24
EP2879683A1 (en) 2015-06-10
ZA201501350B (en) 2016-12-21
EA201590205A1 (ru) 2015-06-30
WO2014022577A1 (en) 2014-02-06
EA027174B1 (ru) 2017-06-30
IN2015DN00538A (es) 2015-06-26
IL236986A (en) 2017-06-29
US9067963B2 (en) 2015-06-30
EP2879683A4 (en) 2016-04-20
JP6545618B2 (ja) 2019-07-17
MX367879B (es) 2019-09-10
AU2013296420B2 (en) 2017-12-07
BR112015002249A2 (pt) 2017-07-04
CA2880040A1 (en) 2014-02-06
EP2879683B1 (en) 2020-01-22
KR20150036767A (ko) 2015-04-07
NZ703992A (en) 2018-04-27
AU2013296420A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
IN2015DN00538A (es)
PH12019500522A1 (en) Tetrahydropyrazolopyrimidine compounds
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
PH12016500642B1 (en) Selective substituted quinoline compounds
MX363708B (es) Compuestos de quinolina selectivamente sustituidos.
MD4650B1 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX378155B (es) Derivados de 9h-pirrolo-dipiridina.
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
GEP20186910B (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
BR112015012720A2 (pt) derivados de feniletilpiridina como inibidores de pde4
PH12015502632A1 (en) Cxcr7 receptor modulators
JO3638B1 (ar) مركبات مفيدة في تثبيط ror - جاما- t
MX2017012783A (es) Carbamatos de alquinilo sustituidos por xantina/carbamatos inversos como antagonistas de a2b.
IN2013MU00665A (es)
MX2016015959A (es) Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3.
MX2012000113A (es) Compuestos alcoxi-carbonil-amino-alquinil-adenosina y derivados de los mismos como agonistas a2ar.
UA111315C2 (uk) Похідні бензімідазолону як інгібітори бромодомену
LV14851A (lv) Triazolilpurīna atvasinājumi kā adenozīna un purīna receptoru agonisti
LV14852A (lv) Triazolilpurīna atvasinājumi kā pretvīrusu preparāti

Legal Events

Date Code Title Description
FG Grant or registration